Saniona highlights Acadia Pharmaceuticals’ upcoming R&D Day

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner, Acadia Pharmaceuticals, is hosting a R&D Day today, where it will provide updates on its neurological and rare disease pipeline, including ACP-711 (formerly SAN711), a program originally developed by Saniona.

ACP-711 is a first-class, highly selective GABA A-α3 positive allosteric modulator, which Saniona outlicensed to Acadia Pharmaceuticals in 2024 for the treatment of neurological diseases. Under the terms of the agreement, Saniona retains the right to receive development, regulatory, and commercial milestones, as well as tiered royalties on future net sales of ACP-711 that may result from its development.

"We are pleased to see ACP-711 progressing under Acadia’s leadership and be part of their upcoming R&D Day. This compound represents a novel mechanism of action for the treatment of neurological disorders, and we look forward to Acadia’s continued advancement of this promising program," said Thomas Feldthus, CEO of Saniona.

Acadia’s R&D Day will be held on Wednesday, 25 June, 2025 at 8:30 AM ET in New York City. The event will feature presentations from Acadia’s management, R&D leadership, key opinion leaders (KOLs), and members of the caregiver community. Registration for the live webcast is available here: https://lifescievents.com/event/acadia-webcast/

Datum 2025-06-25, kl 14:30
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.